



ASX Release

18 July 2019

Zelda Collaborates with Emerald Clinics to Access Real-world Data for Medicinal Cannabis Patients

- **Zelda enters strategic collaboration with Australia-based Emerald Clinics to access clinical data from patients treated with medicinal cannabis for pain and insomnia**
- **Zelda will gain strategic access to:**
 - **Real-world patient data linked to medicinal cannabis prescriptions**
 - **Real-time data from patients treated with Zelda's clinically validated formulations, which the company is aiming to commercially launch in 2020**
 - **Expanded access to new clinical trial sites to accelerate patient recruitment and reduce costs**
- **Emerald collaboration reinforces Zelda's competitive advantage in clinical validation of medicinal cannabis and downstream value-adding**
- **Supports Zelda's path to rapid commercialisation in global markets**

Zelda Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce it has entered into a strategic collaboration with Australia-based healthcare technology and services company Emerald Clinics (**Emerald**), which owns and operates an Australian network of dedicated medicinal cannabis clinics.

Under the terms of the agreement Emerald will provide access to de-identified real-world longitudinal data collected from patients prescribed cannabis medicines for treatment of pain and/or insomnia. Data will include details regarding cannabis dosages prescribed to patients, their responses to treatment and the impact on usage of non-cannabis medicines such as opioids.

This information will inform Zelda's ongoing clinical trial strategy, which is focussed on developing new cannabis-based treatments to reduce opioid usage in patients with chronic pain as well as patients with insomnia and autism.

The agreement also includes an option for Zelda to access real-world data collected from patients prescribed Zelda-branded cannabis products, which the company is aiming to bring

to market in 2020. A further option is for Zelda to engage Emerald to assist with the design and patient recruitment for future clinical trials.

Zelda will pay Emerald an initial fee of \$40,000 to access existing de-identified data for patients prescribed medicinal cannabis for treatment of pain and/or insomnia, while subscription fees for the additional data-modules will be negotiated at a later date.

The strategic collaboration with Emerald further establishes Zelda at the forefront of efforts globally to develop clinically validated cannabis medicines.

Zelda Therapeutics Managing Director, Dr Richard Hopkins, commented: *“Australia’s commitment to developing a highly regulated market for prescription cannabis medicines means this country is now a global leader in collection of high-quality longitudinal clinical data relating to patients treated with medicinal cannabis.*

We believe Emerald’s approach to collection and curation of patient data makes this information a very valuable commodity world-wide.

Being able to access real-world data, in real-time, from patients treated with regulated cannabis medicines – including, in the near future, our own clinically validated products – will provide Zelda with a significant competitive advantage. This information will inform the design of future clinical trials, reduce the risks and costs of development and accelerate the path to market.

These key value-adding features will further differentiate Zelda from its global peers and enhance the commercialisation opportunities for the company.”

Emerald’s Chief Executive Officer, Dr Michael Winlo, said: *“We’re delighted to be working with clinically-focussed companies such as Zelda Therapeutics. This collaboration validates Emerald’s unique care model that emphasises the captures of high-quality data to improve the development of cannabis medicines for patients.”*

Tim Slate

Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- A **human clinical trial program** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A **pre-clinical research program** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelda has also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA's EU- GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.

About Emerald Clinics (www.emeraldclinics.com.au)

Emerald Clinics is a healthcare technology and services company incorporated in March 2018 whose mission is to improve lives, by learning from the experience of every patient that is treated with a cannabinoid medicine. Our team includes specialist physicians, experienced General Practitioners and clinical trials experts to deliver best-practice care for patients who have exhausted conventional therapies in Australia. Emerald Clinics currently has two Australian locations with a third opening in 2019.

For further information contact:

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

Registered Address

Level 26, 140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
E: enquiries@zeldatherapeutics.com